Pulse Biosciences Net Income Over Time
| PLSE Stock | USD 13.83 0.21 1.54% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pulse Biosciences Performance and Pulse Biosciences Correlation. Will Health Care Equipment & Supplies sector continue expanding? Could Pulse diversify its offerings? Factors like these will boost the valuation of Pulse Biosciences. Anticipated expansion of Pulse directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulse Biosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Pulse Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pulse Biosciences' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pulse Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Pulse Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulse Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pulse Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Pulse Biosciences and related stocks such as STAAR Surgical, LifeMD Inc, and Beta Bionics Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STAA | (3.8 M) | 1.3 M | (1.8 M) | 398 K | (8.4 M) | (6.5 M) | (12.1 M) | (2.1 M) | 5 M | 14 M | 5.9 M | 27.5 M | 39.7 M | 21.3 M | (20.2 M) | (23.2 M) | (22.1 M) |
| LFMD | (502.9 K) | (502.9 K) | (445.6 K) | (268.3 K) | (460.5 K) | (62 K) | (1.1 M) | (1.2 M) | (1.2 M) | (3.1 M) | (60.5 M) | (60.9 M) | (45.5 M) | (20.6 M) | (18.9 M) | (17 M) | (17.8 M) |
| BBNX | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (44.1 M) | (54.8 M) | (63 M) | (66.1 M) |
| KMTS | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (34.1 M) | (84.2 M) | (84.2 M) | (94.1 M) | (113.8 M) | (102.4 M) | (107.6 M) |
| IMTX | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.7 M) | (229.3 M) | (95.1 M) | 37.5 M | (97 M) | 15.2 M | 17.5 M | 18.4 M |
| OPK | (2.7 M) | (1.3 M) | (29 M) | (114.4 M) | (171.7 M) | (30 M) | (48.4 M) | (305.2 M) | (153 M) | (314.9 M) | 30.6 M | (30.1 M) | (328.4 M) | (188.9 M) | (53.2 M) | (47.9 M) | (50.3 M) |
| DNTH | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (35.5 M) | (57.5 M) | (76.8 M) | (74.9 M) | (13.1 M) | (28.5 M) | (43.6 M) | (85 M) | (76.5 M) | (72.6 M) |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| NVCR | (77.4 M) | (77.4 M) | (77.4 M) | (77.4 M) | (80.7 M) | (111.6 M) | (131.8 M) | (61.7 M) | (63.6 M) | (7.2 M) | 19.8 M | (58.4 M) | (92.5 M) | (207 M) | (168.6 M) | (151.8 M) | (144.2 M) |
| ATAI | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (169.8 M) | (167.8 M) | (152.4 M) | (40.2 M) | (149.3 M) | (134.3 M) | (141.1 M) |
Pulse Biosciences and related stocks such as STAAR Surgical, LifeMD Inc, and Beta Bionics Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Pulse Biosciences financial statement analysis. It represents the amount of money remaining after all of Pulse Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Pulse Biosciences | PLSE |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 601 Brickell Key |
| Exchange | NASDAQ Exchange |
USD 13.83
Check out Pulse Biosciences Performance and Pulse Biosciences Correlation. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Pulse Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.